ストックスクリーナーアプリを入手
1.27
3.05%
-0.04
前日終値:
$1.31
開ける：
$1.3
24時間の取引高:
11,808
Relative Volume:
0.94
時価総額：
$69.16M
収益：
-
当期純損益:
$-9.51M
株価収益率:
-6.6842
EPS:
-0.19
ネットキャッシュフロー:
$-10.96M
1週間 パフォーマンス:
-6.62%
1か月 パフォーマンス:
-8.63%
6か月 パフォーマンス:
-39.52%
1年 パフォーマンス:
-11.81%
1日の値動き範囲:
$1.27
$1.32
1週間の範囲:
$1.27
$1.361
52週間の値動き範囲:
$1.12
$2.55
Medicinova Inc Stock (MNOV) Company Profile
MNOV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.27 | 69.16M | 0 | -9.51M | -10.96M | -0.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
Medicinova Announces Results of Annual Stockholders Meeting - TipRanks
What is B. Riley’s Forecast for MediciNova Q2 Earnings? - Defense World
MediciNova (NASDAQ:MNOV) Price Target Cut to $5.00 by Analysts at B. Riley - Defense World
MediciNova (MNOV) Stock: Analyst Lowers Price Target, Maintains Buy Rating | MNOV Stock News - GuruFocus
B. Riley Lowers Price Target on MediciNova to $5 From $6, Keeps Buy Rating - MarketScreener
MediciNova, Inc. (NASDAQ:MNOV) Shares Acquired by Bank of America Corp DE - Defense World
Jane Street Group LLC Acquires 9,121 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Bank of America Corp DE Has $696,000 Holdings in Canaan Inc. (NASDAQ:CAN) - Defense World
Type 2 Diabetes Market to Expand Significantly by 2034, States DelveInsight Report | Eli Lilly and Company, Regor Pharma, AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - The Globe and Mail
Diabetes Market to Reach New Heights in Growth by 2032, - openPR.com
StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV) - Defense World
MediciNova: Q1 Earnings Snapshot - San Antonio Express-News
Barclays PLC Purchases 12,800 Shares of MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com - Defense World
StockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV) - Defense World
Geode Capital Management LLC Raises Position in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com - Defense World
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo
MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com - Defense World
MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025 - The Manila Times
MediciNova To Participate in D. Boral’s Capital Global Conference on May 14, 2025 - GlobeNewswire
MediciNova Secures Spotlight at Exclusive Healthcare Conference: CEO to Reveal Latest Pipeline Progress - Stock Titan
Meta CEO Mark Zuckerberg takes the stand in historic antitrust trial - The Globe and Mail
MediciNova’s (MNOV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Texas Instruments (TXN) Stock Trades Down, Here Is Why - The Globe and Mail
First Patient Enrolled in NIH-Funded Expanded Access - GlobeNewswire
First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients - TradingView
This Stock Has More Than Doubled Already in 2025. Is It a Buy? - The Globe and Mail
MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com - Defense World
MEDICINOVA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Why AppLovin (APP) Shares Are Trading Lower Today - The Globe and Mail
MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com - Defense World
Carter's (CRI): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
3 Reasons to Avoid CSX and 1 Stock to Buy Instead - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Top Companies - openPR
Y Intercept Hong Kong Ltd Makes New $78,000 Investment in MediciNova, Inc. (NASDAQ:MNOV) - Defense World
Should You Forget Tesla and Buy 2 Artificial Intelligence (AI) Stocks Right Now? - The Globe and Mail
Pulmonary Fibrosis Therapeutics Market Size in the 7MM - openPR
MKS Instruments to Participate in Cantor Fitzgerald Global Technology Conference - The Globe and Mail
Idiopathic Pulmonary Fibrosis Management Market Key Players - openPR
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - The AM Reporter
MediciNova (NASDAQ:MNOV) Issues Earnings Results - MarketBeat
MediciNova (NASDAQ:MNOV) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
MediciNova (MNOV) to Release Quarterly Earnings on Thursday - MarketBeat
MediciNova (MNOV) Projected to Post Quarterly Earnings on Thursday - Defense World
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.42%
大文字化:
|
ボリューム (24 時間):